365 related articles for article (PubMed ID: 19020901)
1. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.
Xu JM; Han Y; Duan HQ; Gao EM; Zhang Y; Liu XQ; Zhang JS; Toschi L; Galetta D; Azzariti A; Paradiso A
J Cancer Res Clin Oncol; 2009 Jun; 135(6):771-82. PubMed ID: 19020901
[TBL] [Abstract][Full Text] [Related]
2. [Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib].
Han Y; Xu JM; Duan HQ; Zhang Y; Liu XQ; Zhang JS
Chin J Cancer; 2010 Jan; 29(1):69-75. PubMed ID: 20038315
[TBL] [Abstract][Full Text] [Related]
3. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens.
Daniele L; Macrì L; Schena M; Dongiovanni D; Bonello L; Armando E; Ciuffreda L; Bertetto O; Bussolati G; Sapino A
Mol Cancer Ther; 2007 Apr; 6(4):1223-9. PubMed ID: 17406029
[TBL] [Abstract][Full Text] [Related]
4. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
[TBL] [Abstract][Full Text] [Related]
5. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.
Zhang XT; Li LY; Mu XL; Cui QC; Chang XY; Song W; Wang SL; Wang MZ; Zhong W; Zhang L
Ann Oncol; 2005 Aug; 16(8):1334-42. PubMed ID: 15956035
[TBL] [Abstract][Full Text] [Related]
6. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.
Cappuzzo F; Toschi L; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Cancellieri A; Magrini E; Bemis L; Franklin WA; Crino L; Bunn PA; Hirsch FR; Varella-Garcia M
Br J Cancer; 2005 Dec; 93(12):1334-40. PubMed ID: 16288303
[TBL] [Abstract][Full Text] [Related]
7. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
Paz-Ares L; Tan EH; O'Byrne K; Zhang L; Hirsh V; Boyer M; Yang JC; Mok T; Lee KH; Lu S; Shi Y; Lee DH; Laskin J; Kim DW; Laurie SA; Kölbeck K; Fan J; Dodd N; Märten A; Park K
Ann Oncol; 2017 Feb; 28(2):270-277. PubMed ID: 28426106
[TBL] [Abstract][Full Text] [Related]
8. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.
Zhou Q; Zhang XC; Chen ZH; Yin XL; Yang JJ; Xu CR; Yan HH; Chen HJ; Su J; Zhong WZ; Yang XN; An SJ; Wang BC; Huang YS; Wang Z; Wu YL
J Clin Oncol; 2011 Aug; 29(24):3316-21. PubMed ID: 21788562
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer.
Sone T; Kasahara K; Kimura H; Nishio K; Mizuguchi M; Nakatsumi Y; Shibata K; Waseda Y; Fujimura M; Nakao S
Cancer; 2007 May; 109(9):1836-44. PubMed ID: 17387741
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
Bai H; Mao L; Wang HS; Zhao J; Yang L; An TT; Wang X; Duan CJ; Wu NM; Guo ZQ; Liu YX; Liu HN; Wang YY; Wang J
J Clin Oncol; 2009 Jun; 27(16):2653-9. PubMed ID: 19414683
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
Asahina H; Yamazaki K; Kinoshita I; Sukoh N; Harada M; Yokouchi H; Ishida T; Ogura S; Kojima T; Okamoto Y; Fujita Y; Dosaka-Akita H; Isobe H; Nishimura M
Br J Cancer; 2006 Oct; 95(8):998-1004. PubMed ID: 17047648
[TBL] [Abstract][Full Text] [Related]
12. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
Jackman DM; Miller VA; Cioffredi LA; Yeap BY; Jänne PA; Riely GJ; Ruiz MG; Giaccone G; Sequist LV; Johnson BE
Clin Cancer Res; 2009 Aug; 15(16):5267-73. PubMed ID: 19671843
[TBL] [Abstract][Full Text] [Related]
13. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer.
Kimura H; Kasahara K; Shibata K; Sone T; Yoshimoto A; Kita T; Ichikawa Y; Waseda Y; Watanabe K; Shiarasaki H; Ishiura Y; Mizuguchi M; Nakatsumi Y; Kashii T; Kobayashi M; Kunitoh H; Tamura T; Nishio K; Fujimura M; Nakao S
J Thorac Oncol; 2006 Mar; 1(3):260-7. PubMed ID: 17409866
[TBL] [Abstract][Full Text] [Related]
14. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
Cappuzzo F; Varella-Garcia M; Shigematsu H; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Gregorc V; Toschi L; Franklin WA; Crino L; Gazdar AF; Bunn PA; Hirsch FR
J Clin Oncol; 2005 Aug; 23(22):5007-18. PubMed ID: 16051952
[TBL] [Abstract][Full Text] [Related]
15. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.
Tokumo M; Toyooka S; Kiura K; Shigematsu H; Tomii K; Aoe M; Ichimura K; Tsuda T; Yano M; Tsukuda K; Tabata M; Ueoka H; Tanimoto M; Date H; Gazdar AF; Shimizu N
Clin Cancer Res; 2005 Feb; 11(3):1167-73. PubMed ID: 15709185
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
Sugawara S; Oizumi S; Minato K; Harada T; Inoue A; Fujita Y; Maemondo M; Yoshizawa H; Ito K; Gemma A; Nishitsuji M; Harada M; Isobe H; Kinoshita I; Morita S; Kobayashi K; Hagiwara K; Kurihara M; Nukiwa T
Ann Oncol; 2015 May; 26(5):888-894. PubMed ID: 25669832
[TBL] [Abstract][Full Text] [Related]
17. Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer.
Oshita F; Matsukuma S; Yoshihara M; Sakuma Y; Ohgane N; Kameda Y; Saito H; Yamada K; Tsuchiya E; Miyagi Y
Br J Cancer; 2006 Oct; 95(8):1070-5. PubMed ID: 17047654
[TBL] [Abstract][Full Text] [Related]
18. Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.
Han SW; Kim TY; Lee KH; Hwang PG; Jeon YK; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ
Lung Cancer; 2006 Nov; 54(2):201-7. PubMed ID: 16956694
[TBL] [Abstract][Full Text] [Related]
19. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
Varella-Garcia M; Mitsudomi T; Yatabe Y; Kosaka T; Nakajima E; Xavier AC; Skokan M; Zeng C; Franklin WA; Bunn PA; Hirsch FR
J Thorac Oncol; 2009 Mar; 4(3):318-25. PubMed ID: 19247083
[TBL] [Abstract][Full Text] [Related]
20. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
